186 related articles for article (PubMed ID: 35725813)
21. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
Corre S; Tardif N; Mouchet N; Leclair HM; Boussemart L; Gautron A; Bachelot L; Perrot A; Soshilov A; Rogiers A; Rambow F; Dumontet E; Tarte K; Bessede A; Guillemin GJ; Marine JC; Denison MS; Gilot D; Galibert MD
Nat Commun; 2018 Nov; 9(1):4775. PubMed ID: 30429474
[TBL] [Abstract][Full Text] [Related]
22. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
23.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
24. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
[TBL] [Abstract][Full Text] [Related]
25. Targeting CDC7 sensitizes resistance melanoma cells to BRAF
Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY
Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454
[TBL] [Abstract][Full Text] [Related]
26. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
27. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
28. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
30. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
31. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
[TBL] [Abstract][Full Text] [Related]
32. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
33. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
Wu PK; Hong SK; Park JI
Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
[TBL] [Abstract][Full Text] [Related]
34. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
35. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
37. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
38. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
39. The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.
Babagana M; Kichina JV; Slabodkin H; Johnson S; Maslov A; Brown L; Attwood K; Nikiforov MA; Kandel ES
Mol Carcinog; 2020 Jan; 59(1):5-14. PubMed ID: 31571292
[TBL] [Abstract][Full Text] [Related]
40. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
